Clinical Trial Update: A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 open-label dose-escalation study of ANG1005 in patients with malignant glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• ANG1005 (GRN1005)

Snippet

Sponsor: Angiochem Inc | Conditions: Recurrent or Progressive Malignant Glioma | Phase 1 | Status: COMPLETED